News
Feb 22, 2020
The Amyloidosis Foundationexternal link, opens in a new tab is proud to be a partner at this event, Amyloidosis: A Disease Now at the Forefront of Practice Latest…
AbstractAlzheimer’s disease (AD) is the most prevalent neurodegenerative disorder. Antiamyloid antibody treatments modestly slow disease progression in mild…
Cardiac Amyloidosis - What You Need to Know
January 20, 2024
12PM - 2:30PM ET
Please join Amyloidosis Support Groups on January 20th from 12:00 pm - 2:30 pm ET for…
Calquence six-year follow-up data reinforce long-term benefit in chronic lymphocytic
leukaemia, and data across multiple haematology assets showcase breadth of…
We invite you to attend the XIX International Symposium on Amyloidosis to be held in Rochester, MN.
This symposium is organized as a hybrid meeting (with the focus…
Hereditary transthyretin (hATTR) amyloidosis, also known as variant ATTR (ATTRv) amyloidosis, is a rare disease affecting about 50,000 people worldwide. It's caused…
Published: Oct 09, 2023
- FDA Cites Insufficient Evidence of Clinical Meaningfulness -
- No Clinical Safety, Study Conduct, Drug Quality or Manufacturing…
- Cardiovascular and Renal Drugs Advisory Committee Voted 9:3 That the Benefits of Patisiran Outweigh its Risks for the Treatment of the Cardiomyopathy of ATTR…
Kochi: India's first center of excellence for the evaluation and treatment of patients with suspected or established amyloidosis was launched today at Amrita…